CA2396561C - Substituted oxazolidinones and their use in the field of blood coagulation - Google Patents

Substituted oxazolidinones and their use in the field of blood coagulation Download PDF

Info

Publication number
CA2396561C
CA2396561C CA002396561A CA2396561A CA2396561C CA 2396561 C CA2396561 C CA 2396561C CA 002396561 A CA002396561 A CA 002396561A CA 2396561 A CA2396561 A CA 2396561A CA 2396561 C CA2396561 C CA 2396561C
Authority
CA
Canada
Prior art keywords
compound
hydrate
salt
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002396561A
Other languages
English (en)
French (fr)
Other versions
CA2396561A1 (en
Inventor
Alexander Straub
Thomas Lampe
Jens Pohlmann
Susanne Rohrig
Elisabeth Perzborn
Karl-Heinz Schlemmer
Joseph Pernerstorfer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7934434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2396561(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of CA2396561A1 publication Critical patent/CA2396561A1/en
Application granted granted Critical
Publication of CA2396561C publication Critical patent/CA2396561C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002396561A 1999-12-24 2000-12-11 Substituted oxazolidinones and their use in the field of blood coagulation Expired - Lifetime CA2396561C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19962924.2 1999-12-24
DE19962924A DE19962924A1 (de) 1999-12-24 1999-12-24 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2000/012492 WO2001047919A1 (de) 1999-12-24 2000-12-11 Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung

Publications (2)

Publication Number Publication Date
CA2396561A1 CA2396561A1 (en) 2001-07-05
CA2396561C true CA2396561C (en) 2008-10-14

Family

ID=7934434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396561A Expired - Lifetime CA2396561C (en) 1999-12-24 2000-12-11 Substituted oxazolidinones and their use in the field of blood coagulation

Country Status (48)

Country Link
US (8) US7157456B2 (en:Method)
EP (2) EP1261606B1 (en:Method)
JP (2) JP4143297B2 (en:Method)
KR (3) KR20070044075A (en:Method)
CN (3) CN1900074B (en:Method)
AR (1) AR032436A1 (en:Method)
AT (1) ATE289605T1 (en:Method)
AU (2) AU775126C (en:Method)
BE (1) BE2008C046I2 (en:Method)
BG (1) BG65683B1 (en:Method)
BR (1) BR0017050B1 (en:Method)
CA (1) CA2396561C (en:Method)
CO (1) CO5251440A1 (en:Method)
CU (2) CU23208A3 (en:Method)
CY (2) CY2008019I1 (en:Method)
CZ (1) CZ301432B6 (en:Method)
DE (3) DE19962924A1 (en:Method)
DK (2) DK1526132T3 (en:Method)
DO (2) DOP2000000114A (en:Method)
EE (1) EE05169B1 (en:Method)
ES (2) ES2237497T3 (en:Method)
FR (1) FR08C0051I2 (en:Method)
GT (1) GT200000216A (en:Method)
HN (1) HN2000000267A (en:Method)
HR (2) HRP20060251B1 (en:Method)
HU (1) HU226522B1 (en:Method)
IL (2) IL149896A0 (en:Method)
LT (1) LTC1261606I2 (en:Method)
LU (1) LU91497I2 (en:Method)
MA (1) MA25646A1 (en:Method)
MX (1) MXPA02006241A (en:Method)
MY (1) MY140488A (en:Method)
NL (1) NL300370I2 (en:Method)
NO (4) NO323699B1 (en:Method)
NZ (2) NZ537058A (en:Method)
PE (1) PE20010963A1 (en:Method)
PL (2) PL201121B1 (en:Method)
PT (2) PT1526132E (en:Method)
SG (1) SG130939A1 (en:Method)
SI (2) SI1526132T1 (en:Method)
SK (1) SK287272B6 (en:Method)
SV (1) SV2002000245A (en:Method)
TR (2) TR200201636T2 (en:Method)
TW (2) TWI277615B (en:Method)
UA (1) UA73339C2 (en:Method)
UY (1) UY34152A (en:Method)
WO (1) WO2001047919A1 (en:Method)
ZA (1) ZA200204188B (en:Method)

Families Citing this family (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003106413A2 (en) * 2001-10-18 2003-12-24 Michigan State University Process for the preparation of oxazolidinones and method of use thereof
DE10152460A1 (de) * 2001-10-24 2003-05-08 Bayer Ag Stents
EP1443930A1 (en) 2001-10-25 2004-08-11 AstraZeneca AB Isoxazoline derivatives useful as antimicrobials
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US7012088B2 (en) 2003-02-24 2006-03-14 Pharmacia & Upjohn Company Indolone oxazolidinones and derivatives thereof
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
DE10336716A1 (de) * 2003-08-11 2005-03-10 Merck Patent Gmbh Verfahren zur Herstellung von N-Aryl-morpholinonen
DE10342570A1 (de) 2003-09-15 2005-04-14 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MXPA06013213A (es) * 2004-05-13 2007-02-08 Boehringer Ingelheim Int Nuevas amidas sustituidas del acido tiofencarboxilico, su obtencion y su uso como medicamentos.
EP1748997A1 (de) * 2004-05-13 2007-02-07 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
EP1893572B1 (en) * 2004-06-18 2016-12-14 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
PE20060619A1 (es) 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
DE102004050283A1 (de) * 2004-10-15 2006-04-27 Lanxess Deutschland Gmbh 4-Aminophenyl-morpholinon-Derivate und deren Herstellung
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
NZ555289A (en) 2004-10-22 2010-10-29 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005018690A1 (de) * 2005-04-22 2006-10-26 Bayer Healthcare Ag Imino-oxazolidine und ihre Verwendung
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
JP2008543972A (ja) 2005-06-27 2008-12-04 ブリストル−マイヤーズ スクイブ カンパニー 血栓症状の治療に有用なｐ２ｙ１受容体のｎ−結合複素環式アンタゴニスト
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
PE20070171A1 (es) * 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
WO2007007588A1 (ja) * 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
US20070032473A1 (en) * 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
AR057976A1 (es) * 2005-08-29 2008-01-09 Boehringer Ingelheim Int Biarilos sustituidos y su uso como medicamentos.
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US8188270B2 (en) * 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102005048824A1 (de) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
CA2626623C (en) 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
US7962847B2 (en) * 2005-10-20 2011-06-14 International Business Machines Corporation Method for providing dynamic process step annotations
DE102005052174A1 (de) 2005-11-02 2007-06-06 Bayer Healthcare Ag Phenylen-bis-oxazolidin-Derivate und ihre Verwendung
JP2007154330A (ja) * 2005-12-01 2007-06-21 Nippon Paper Industries Co Ltd 印刷用塗工紙
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
KR20080110877A (ko) 2006-03-31 2008-12-19 재단법인 이쯔우 연구소 헤테로환을 갖는 신규 화합물
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
NZ572073A (en) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocyclic compounds as inhibitors of c-fms kinase
MX2008013530A (es) 2006-04-20 2009-01-14 Janssen Pharmaceutica Nv Inhibidores de c-fms cinasa.
EA016611B1 (ru) 2006-04-20 2012-06-29 Янссен Фармацевтика Н.В. Способ лечения мастоцитоза
US8674100B2 (en) 2006-04-20 2014-03-18 Janssen Pharmaceutica, N.V. Inhibitors of C-FMS kinase
NZ572418A (en) 2006-05-05 2011-08-26 Millennium Pharm Inc Factor xa inhibitors
DE102006025314A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Arylsubstituierte Heterozyklen und ihre Verwendung
DE102006025319A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Aktiengesellschaft Substituierte Heterozyklen und ihre Verwendung
DE102006034916A1 (de) * 2006-07-28 2008-01-31 Bayer Healthcare Ag Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2114930A2 (en) * 2007-01-05 2009-11-11 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
WO2008120655A1 (ja) 2007-03-30 2008-10-09 Institute Of Medicinal Molecular Design, Inc. Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体
DE102007018662A1 (de) * 2007-04-20 2008-10-23 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von pulmonaler Hypertonie
AU2008241091B2 (en) 2007-04-23 2013-05-09 Sanofi-Aventis Quinoline-carboxamide derivatives as P2Y12 antagonists
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
KR101009594B1 (ko) 2007-05-09 2011-01-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028318A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007037373A1 (de) 2007-08-06 2009-02-19 Schebo Biotech Ag Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
WO2009018807A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
US20090076264A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched rivaroxaban
EP2233484A3 (en) 2007-10-02 2012-04-04 Research Foundation Itsuu Laboratory Oxazolidinone derivatives having a 7-membered heterocyclic ring
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
JP5524852B2 (ja) * 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミド、それらの製造及び医薬品としての使用
NZ586002A (en) * 2007-12-11 2012-06-29 Bayer Schering Pharma Ag Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
DE102008028071A1 (de) * 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
EP2138178A1 (en) * 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
KR100898361B1 (ko) * 2008-07-03 2009-05-20 주식회사 레고켐 바이오사이언스 Ｐ4 위치에 사이클릭 아미독심 또는 사이클릭 아미드라존기를 가지는 ＦＸａ 저해제, 이의 유도체, 제조방법 및이를 함유하는 의약 조성물
EP2140866A1 (en) * 2008-07-04 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
JP2011527297A (ja) 2008-07-08 2011-10-27 ラーツイオフアルム・ゲー・エム・ベー・ハー ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（３−オキソ−４−モルホリニル）−フェニル］−１，３−オキサゾリジン−５−イル｝−メチル）−２−チオフェンカルボキサミドを含む医薬組成物
KR101023174B1 (ko) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 사이클릭 아미독심 또는 사이클릭 아미드라존 기를 가지는 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
EP2400964A4 (en) * 2009-01-30 2012-08-01 Glaxosmithkline Llc CRYSTALLINES N - {(1-S) -2-AMINO-1 - [(3-FLUORPHENYL) METHYL] ETHYL} -5-CHLORO-4- (4-CHLORO-1-METHYL-1H-PYRAZOL-5-YL) -2-THIOPHENCARBOXAMID HYDROCHLORIDE
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
ES2606127T5 (es) 2009-06-18 2020-02-17 Krka Tovarna Zdravil D D Novo Mesto Composición farmacéutica sólida que comprende rivaroxabán
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
KR101037051B1 (ko) * 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 (ｓ)-5-클로로-ｎ-((3-(4-(5,6-다이하이드로-4ｈ-1,2,4-옥사다이아진-3-일)페닐)-2-옥소옥사졸리딘-5-일)메틸)싸이오펜-2-카르복사미드 유도체의 제조방법
KR101037052B1 (ko) * 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 5-클로로-ｎ-(((5ｓ)-2-옥소-3-(4-(5,6-디하이드로-1,2,4-트리아진-1(4ｈ)-일)페닐)-1,3-옥사졸리딘-5-일)메틸)티오펜-2-카르복사미드 유도체의 제조방법 및 그 제조중간체
EA031064B2 (ru) * 2009-07-31 2020-07-01 КРКА, д.д., НОВО МЕСТО Способы кристаллизации ривароксабана
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
EP2485715A1 (en) 2009-10-06 2012-08-15 Ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
WO2011061760A1 (en) * 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
CN102762550B (zh) 2009-12-17 2015-04-01 米伦纽姆医药公司 Xa因子抑制剂的盐和结晶形式
WO2011075602A1 (en) * 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
WO2011080341A1 (en) 2010-01-04 2011-07-07 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
US8940720B2 (en) 2010-02-11 2015-01-27 Bristol-Myers Squibb Company Macrocycles as factor XIa inhibitors
EA015918B1 (ru) 2010-03-03 2011-12-30 Дмитрий Геннадьевич ТОВБИН УРЕТАНЫ, МОЧЕВИНЫ, АМИДЫ И РОДСТВЕННЫЕ ИНГИБИТОРЫ ФАКТОРА Xa
DE102010018299A1 (de) 2010-04-23 2011-10-27 Archimica Gmbh Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
EP2388260A1 (de) 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN107021932A (zh) * 2010-06-29 2017-08-08 欧美嘉股份有限公司 制备5‑左旋‑氨甲基‑3‑芳基‑2‑恶唑烷酮类的方法
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) * 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) 2010-09-30 2012-04-11 Farmak, A. S. Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
EP2630143B1 (en) * 2010-10-18 2017-11-29 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
DE102010063127A1 (de) 2010-12-15 2012-06-21 Bayer Schering Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
CN102199150A (zh) * 2011-04-01 2011-09-28 中国药科大学 光学活性噁唑烷酮类衍生物及其制备方法与在制药中的用途
EP2697209B1 (en) 2011-04-11 2015-09-23 Sandoz AG Method for the preparation of substituted oxazolidinones
EP2705028B1 (en) 2011-05-06 2019-08-21 Egis Gyógyszergyár Zrt. Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (es) * 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
CN102796092B (zh) * 2011-05-24 2015-04-08 北大方正集团有限公司 噁唑烷酮衍生物及其制备方法和应用
CN102796091A (zh) * 2011-05-24 2012-11-28 北大方正集团有限公司 取代的噁唑烷酮化合物及其制备方法和应用
CN102320988B (zh) * 2011-06-03 2014-04-09 中国科学院上海有机化学研究所 4-(4-氨基苯基)-3-吗啉酮中间体酰胺、合成方法和用途
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
EP2753619A2 (en) 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
EP2573084A1 (en) 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof
HU230734B1 (hu) 2011-10-10 2017-12-28 EGIS Gyógyszergyár Nyrt Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
WO2013053739A1 (en) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
WO2013054275A1 (en) * 2011-10-11 2013-04-18 Council Of Scientific & Industrial Research Sila analogs of oxazolidinone derivatives and synthesis thereof
MY165742A (en) 2011-10-14 2018-04-23 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
IN2014CN02806A (en:Method) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
IN2014CN02805A (en:Method) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
CN102408420B (zh) * 2011-10-19 2014-10-22 汕头经济特区鮀滨制药厂 一种利伐沙班及其中间体的制备方法以及中间体化合物
US20150011756A1 (en) 2012-02-06 2015-01-08 Megafine Pharma (P) Ltd Process for preparation of rivaroxaban and intermediates thereof
CZ2012111A3 (cs) 2012-02-16 2013-08-28 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na vyuzití (S)-epichlorhydrinu
CZ2012114A3 (cs) 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
WO2013151719A2 (en) * 2012-04-05 2013-10-10 Scifluor Life Sciences, Llc Fluorinated oxazolidinone derivatives
EP2834235A1 (en) 2012-04-06 2015-02-11 Indiana University Research and Technology Corporation Processes for preparing rivaroxaban
AU2013250801A1 (en) 2012-04-16 2014-11-06 Sun Pharmaceutical Industries Limited Process for the preparation of rivaroxaban and intermediates thereof
WO2013164833A1 (en) 2012-05-02 2013-11-07 Symed Labs Limited Improved process for preparing rivaroxaban using novel intermediates
SG11201407518SA (en) * 2012-05-24 2014-12-30 Ranbaxy Lab Ltd Process for the preparation of rivaroxaban
CN102746287B (zh) * 2012-06-21 2014-05-28 成都苑东药业有限公司 一种恶唑烷酮化合物及其制备方法
UY34856A (es) 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
CN102757424B (zh) * 2012-07-09 2014-10-15 云南大学 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
DK2880026T3 (en) 2012-08-03 2017-06-06 Bristol Myers Squibb Co DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS
SG11201500270RA (en) 2012-08-03 2015-03-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
CN103626749A (zh) * 2012-08-21 2014-03-12 苏州泽璟生物制药有限公司 取代的噁唑烷酮化合物和包含该化合物的药物组合物及其用途
IN2015DN02600A (en:Method) 2012-09-26 2015-09-18 Ranbaxy Lab Ltd
CN103864773B (zh) * 2012-12-13 2017-03-15 北京藏卫信康医药研发有限公司 利伐沙班及其中间体的制备方法
EP2935255B1 (en) 2012-12-21 2017-08-16 Farma GRS, d.o.o. A process for preparation of rivaroxaban
US9394292B2 (en) 2012-12-26 2016-07-19 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof
WO2014102822A2 (en) 2012-12-26 2014-07-03 Wanbury Ltd. Aldehyde derivative of substitute oxazolidinones
WO2014155259A2 (en) * 2013-03-25 2014-10-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of rivaroxaban
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
CN104098556B (zh) * 2013-04-09 2019-01-08 浙江九洲药物科技有限公司 一种利伐沙班的合成工艺
CN104163819A (zh) * 2013-05-17 2014-11-26 天津药物研究院 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
CA2914040A1 (en) * 2013-06-03 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
JP2016520110A (ja) 2013-06-03 2016-07-11 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンゾキサゾール
UY35592A (es) 2013-06-03 2014-12-31 Bayer Pharma AG Benzoxazoles sustituidos
WO2015011617A1 (en) 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of rivaroxaban
US9598403B2 (en) 2013-08-19 2017-03-21 Amneal Pharmaceuticals Llc Process for the preparation of rivaroxaban
IN2014MU00072A (en:Method) 2014-01-08 2015-08-21 Wockhardt Ltd
IN2014CH00290A (en:Method) 2014-01-23 2015-08-14 Symed Labs Ltd
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (en:Method) 2014-01-31 2018-03-10
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104974149B (zh) * 2014-04-14 2018-05-01 北大方正集团有限公司 一种利伐沙班的制备方法
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
CN105085371B (zh) * 2014-04-22 2017-06-16 北大方正集团有限公司 (s)‑{1‑(氯甲酸酯基)‑2‑[2‑(1,3‑二氧异吲哚)基]乙基}卤化盐及其制备方法
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
WO2015169957A1 (en) 2014-05-09 2015-11-12 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and h2-receptor antagonists
CN104031036A (zh) * 2014-05-16 2014-09-10 南通常佑药业科技有限公司 一种利伐沙班的制备方法
JP2017516845A (ja) 2014-05-22 2017-06-22 ノース チャイナ ファーマシューティカル カンパニー リミテッド 血液凝固因子Ｘａ阻害剤としてのヒドラジド化合物
CN103980221B (zh) * 2014-05-26 2016-03-23 山东康美乐医药科技有限公司 4-（硝基苯基）-3-吗啉酮的制备方法及利用其制备利伐沙班的方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2015198259A1 (en) 2014-06-26 2015-12-30 Erregierre S.P.A. Process for the synthesis of rivaroxaban and intermediate for the production thereof
RS57732B1 (sr) 2014-07-15 2018-12-31 Gruenenthal Gmbh Supstituisani derivati azaspiro(4.5)dekana
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
CN104086539A (zh) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 一种利伐沙班的制备方法
EP3186246A1 (en) 2014-08-25 2017-07-05 Cipla Limited Process for the preparation of rivaroxaban
NO2721243T3 (en:Method) 2014-10-01 2018-10-20
CN104356124A (zh) * 2014-10-30 2015-02-18 广东东阳光药业有限公司 噁唑烷酮类化合物及其组合物和用途
CN104402876A (zh) * 2014-11-25 2015-03-11 沈阳药科大学 噁唑烷酮类化合物及其应用
CN104478869B (zh) * 2014-12-05 2017-04-12 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104447728B (zh) * 2014-12-05 2017-01-04 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104478866B (zh) * 2014-12-05 2017-07-07 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530029B (zh) * 2014-12-09 2017-04-12 广东东阳光药业有限公司 作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104496978A (zh) * 2014-12-09 2015-04-08 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
CN104497008B (zh) * 2014-12-09 2016-11-16 广东东阳光药业有限公司 取代噁唑烷酮类化合物及其使用方法和用途
CN104530031A (zh) * 2014-12-10 2015-04-22 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530080B (zh) * 2014-12-10 2017-01-11 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN104530030A (zh) * 2014-12-10 2015-04-22 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
CN105777734A (zh) * 2014-12-22 2016-07-20 常州方楠医药技术有限公司 一种利伐沙班中间体的合成方法
CN104557900A (zh) * 2014-12-23 2015-04-29 中国药科大学 噁唑烷酮类化合物及其制备方法与医药用途
CN105820161A (zh) * 2015-01-08 2016-08-03 常州方楠医药技术有限公司 一种利伐沙班中间体5-羟基甲基噁唑烷酮衍生物的合成方法
TR201501970A2 (en) 2015-02-19 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dronedarone.
SG11201707050VA (en) 2015-03-20 2017-10-30 Hoffmann La Roche Bace1 inhibitors
WO2016150937A1 (en) 2015-03-25 2016-09-29 Lonza Ltd Method for preparation of thiophenecarbonyl chlorides
CN104926807B (zh) * 2015-06-04 2017-10-31 沈阳药科大学 一种利伐沙班相关物质“二胺”及其合成方法
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
JP6816103B2 (ja) 2015-07-29 2021-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 非芳香族性Ｐ２’基を担持する新規大員環の第ＸＩａ因子阻害剤
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
TW201720807A (zh) * 2015-11-04 2017-06-16 隆薩有限公司 用草醯氯製備噻吩-2-羰醯氯的方法
PT3377176T (pt) 2016-02-23 2022-01-13 Morgandane Scient Llc Método de tratamento de pacientes aos quais foram coadministrados rivaroxabano e verapamil
WO2017151746A1 (en) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
EP3263096B1 (en) 2016-06-28 2025-07-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical capsule composition of rivaroxaban
CN106588905A (zh) * 2016-12-13 2017-04-26 重庆英斯凯化工有限公司 一种利伐沙班中间体的制备方法
US11034683B2 (en) 2017-01-04 2021-06-15 Unichem Laboratories Ltd Process for the preparation of rivaroxaban involving novel intermediate
CN107586291B (zh) * 2017-11-03 2019-08-20 梯尔希（南京）药物研发有限公司 一种利伐沙班代谢物5的合成方法
CN107857761A (zh) * 2017-11-14 2018-03-30 安徽华胜医药科技有限公司 一种氘代利伐沙班及其制备方法
CN107857739A (zh) * 2017-11-14 2018-03-30 安徽华胜医药科技有限公司 一种氘代利伐沙班关键中间体及其制备方法
CN108164519A (zh) * 2017-12-28 2018-06-15 江苏悦兴医药技术有限公司 利伐沙班工艺杂质的合成方法
EP3505160A1 (en) 2017-12-31 2019-07-03 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof
HU231119B1 (hu) 2018-01-12 2020-11-30 Richter Gedeon Nyrt. Eljárás 4-(4-aminofenil)morfolin-3-on előállítására
US10828310B2 (en) 2018-02-02 2020-11-10 Bayer Pharma Aktiengesellschaft Reducing the risk of cardiovascular events
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
CN108546265A (zh) * 2018-06-22 2018-09-18 苏州中联化学制药有限公司 一种利伐沙班中间体的合成方法
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
WO2020101587A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising rivaroxaban
CN110054621A (zh) * 2019-03-12 2019-07-26 浙江天宇药业股份有限公司 一种利伐沙班中间体的制备方法
CN110615756A (zh) * 2019-06-28 2019-12-27 南京红杉生物科技有限公司 1-(4-硝基苯基)哌啶-2-酮及其合成方法和应用
US11608320B2 (en) 2020-02-02 2023-03-21 Kuwait University Oxazolidinone hydroxamic acid derivatives
CN111253383A (zh) * 2020-03-27 2020-06-09 南京国星生物技术研究院有限公司 一种利伐沙班的合成方法
CN112159402B (zh) * 2020-10-28 2022-04-05 南京法恩化学有限公司 一种利伐沙班的制备方法
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CN115260117B (zh) * 2022-08-09 2024-05-28 江苏法安德医药科技有限公司 一种4-(4-氨基苯基)吗啡啉-3-酮的合成方法
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1035546B (de) 1955-02-16 1958-07-31 Max Ruf Torbegrenzung fuer Ballspiele
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES533097A0 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
ATE95176T1 (de) 1987-10-21 1993-10-15 Du Pont Merck Pharma Aminomethyl-oxo-oxazolidinyl-ethenylbenzenderivate, nuetzlich als antibakterielles mittel.
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
JP3176626B2 (ja) 1991-11-01 2001-06-18 ファルマシア・アンド・アップジョン・カンパニー 抗菌剤として有用な置換アリール−およびヘテロアリールフェニルオキサゾリジノン類
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
CZ231497A3 (cs) 1995-02-03 1998-08-12 Pharmacia & Upjohn Company Antimikrobiální fenyloxazolidinony substituované heteroaromatickým kruhem
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH11512386A (ja) 1995-09-01 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー ４−８員複素環へのｃ−ｃ結合を有するフェニルオキサゾリジノン
ATE257829T1 (de) 1995-09-15 2004-01-15 Upjohn Co Aminoaryl oxazolidinone n-oxide
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DK0930076T3 (da) 1996-07-15 2005-01-31 Sankyo Co Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
FI19992555L (fi) 1997-05-30 1999-11-30 Upjohn Co Antibakteerisia oksatosolidinoniaineita, joilla on tiokarbonyylifunktionaalisuus
EP0994874A1 (en) 1997-07-11 2000-04-26 PHARMACIA & UPJOHN COMPANY Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
WO1999024428A1 (en) 1997-11-12 1999-05-20 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
DE19802239A1 (de) 1998-01-22 1999-07-29 Bayer Ag Neue mit Bicyclen substituierte Oxazolidinone
CN1288462A (zh) 1998-01-23 2001-03-21 法玛西雅厄普约翰美国公司 噁唑烷酮组合库、组合物和制备方法
SK11082000A3 (sk) 1998-01-27 2001-01-18 Aventis Pharmaceuticals Products Inc. Substituované oxoazaheterocyklické inhibítory faktora xa, farmaceutický prostriedok s ich obsahom a ich použitie
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
ES2182521T3 (es) 1998-05-18 2003-03-01 Upjohn Co Mejoramiento de la actividad de agentes antibacterianos de oxazolidinona mediante derivados de arginina.
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
EA005567B1 (ru) 1999-12-21 2005-04-28 Фармация Энд Апджон Компани Оксазолидиноны, обладающие сульфоксиминовой функциональностью
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU2225901A (en) 1999-12-28 2001-07-09 Ajinomoto Co., Inc. Aspartame derivative crystals
KR100415318B1 (ko) 2000-09-23 2004-01-16 탁승호 레이저를 이용한 수평 및 수직선 지시계
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
AU2006214534B2 (en) 2005-02-14 2012-07-19 Epitopix, Llc Polypeptides from Staphylococcus aureus and methods of use
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
KR101378695B1 (ko) * 2007-04-18 2014-03-31 삼성전자주식회사 통신 시스템에서의 훈련 시퀀스 코드 생성 방법 및 장치

Also Published As

Publication number Publication date
HN2000000267A (es) 2001-06-13
US20150166568A1 (en) 2015-06-18
US20030153610A1 (en) 2003-08-14
EE200200341A (et) 2003-10-15
NO20023043D0 (no) 2002-06-21
DK1261606T3 (da) 2005-05-09
TWI277615B (de) 2007-04-01
SK9082002A3 (en) 2003-04-01
US7592339B2 (en) 2009-09-22
DOP2000000114A (es) 2002-07-15
BG106825A (en) 2003-02-28
US7585860B2 (en) 2009-09-08
CN1262551C (zh) 2006-07-05
HRP20060251A2 (en) 2006-12-31
CY2008019I2 (el) 2009-11-04
CY1115117T1 (el) 2016-12-14
EP1526132B1 (de) 2014-03-12
EE05169B1 (et) 2009-06-15
WO2001047919A1 (de) 2001-07-05
US20080200674A1 (en) 2008-08-21
SK287272B6 (sk) 2010-05-07
UY34152A (es) 2013-02-28
TR200401314T2 (tr) 2004-08-23
IL205242A (en) 2011-12-29
CY2008019I1 (el) 2009-11-04
BR0017050A (pt) 2002-11-05
FR08C0051I1 (en:Method) 2008-10-17
US20130005701A1 (en) 2013-01-03
NO2009001I1 (no) 2009-02-02
NO2021009I1 (no) 2021-02-25
PL355665A1 (en) 2004-05-04
HRP20020617B1 (en) 2006-09-30
AU775126C (en) 2005-09-01
HK1103235A1 (en) 2007-12-14
NZ537058A (en) 2006-04-28
US7576111B2 (en) 2009-08-18
CU23423B7 (es) 2009-09-08
CU23208A3 (es) 2007-06-20
US20130316999A1 (en) 2013-11-28
HK1092140A1 (zh) 2007-02-02
IL205242A0 (en) 2011-07-31
ES2457021T3 (es) 2014-04-24
HU226522B1 (en) 2009-03-30
RU2002120456A (ru) 2004-01-10
NO20023043L (no) 2002-08-14
CN100549008C (zh) 2009-10-14
PT1261606E (pt) 2005-07-29
BR0017050B1 (pt) 2012-06-12
CN1900074A (zh) 2007-01-24
DK1526132T3 (da) 2014-06-16
NZ519730A (en) 2005-02-25
KR100804932B1 (ko) 2008-02-20
CZ301432B6 (cs) 2010-03-03
AU2841401A (en) 2001-07-09
KR20070044075A (ko) 2007-04-26
JP4143297B2 (ja) 2008-09-03
US20100137274A1 (en) 2010-06-03
ATE289605T1 (de) 2005-03-15
EP1526132A2 (de) 2005-04-27
JP2005068164A (ja) 2005-03-17
NO20070981L (no) 2002-08-14
ZA200204188B (en) 2003-05-27
NO323699B1 (no) 2007-06-25
BE2008C046I2 (en:Method) 2019-12-16
CN1772751A (zh) 2006-05-17
MA25646A1 (fr) 2002-12-31
LTPA2008018I1 (lt) 2021-04-12
JP5190173B2 (ja) 2013-04-24
AU2004218729A1 (en) 2004-11-04
EP1526132A3 (de) 2005-08-31
PL200413B1 (pl) 2009-01-30
US7157456B2 (en) 2007-01-02
PL201121B1 (pl) 2009-03-31
HRP20020617A2 (en) 2004-12-31
PE20010963A1 (es) 2001-11-10
LTC1261606I2 (lt) 2021-05-10
LU91497I2 (fr) 2009-01-19
CA2396561A1 (en) 2001-07-05
DE19962924A1 (de) 2001-07-05
NL300370I1 (nl) 2009-02-02
NL300370I2 (nl) 2009-05-06
CN1434822A (zh) 2003-08-06
MY140488A (en) 2009-12-31
DE122009000014I1 (de) 2009-11-05
EP1261606B1 (de) 2005-02-23
GT200000216A (es) 2002-06-12
EP1261606A1 (de) 2002-12-04
HUP0203902A2 (hu) 2003-03-28
KR20020067569A (ko) 2002-08-22
HK1057556A1 (en) 2004-04-08
RU2297415C2 (ru) 2007-04-20
TW200422299A (en) 2004-11-01
CN1900074B (zh) 2012-07-11
US20080090815A1 (en) 2008-04-17
US8129378B2 (en) 2012-03-06
CO5251440A1 (es) 2003-02-28
US20060258724A1 (en) 2006-11-16
NO2009001I2 (en:Method) 2010-05-11
US8822458B2 (en) 2014-09-02
WO2001047919A9 (de) 2002-12-19
AR032436A1 (es) 2003-11-12
DOP2008000001A (es) 2010-01-15
LU91497I9 (en:Method) 2019-01-02
UA73339C2 (en) 2005-07-15
MXPA02006241A (es) 2003-01-28
KR20070094672A (ko) 2007-09-20
IL149896A0 (en) 2002-11-10
HUP0203902A3 (en) 2003-07-28
SV2002000245A (es) 2002-01-15
DE50009607D1 (de) 2005-03-31
FR08C0051I2 (fr) 2009-12-18
SI1261606T1 (en:Method) 2005-08-31
HRP20060251B1 (hr) 2016-08-12
TWI226330B (en) 2005-01-11
PT1526132E (pt) 2014-04-15
SI1526132T1 (sl) 2014-07-31
AU775126B2 (en) 2004-07-15
TR200201636T2 (tr) 2002-10-21
BG65683B1 (bg) 2009-06-30
SG130939A1 (en) 2007-04-26
ES2237497T3 (es) 2005-08-01
CZ20022202A3 (cs) 2002-11-13
US8530505B2 (en) 2013-09-10
JP2003519141A (ja) 2003-06-17

Similar Documents

Publication Publication Date Title
CA2396561C (en) Substituted oxazolidinones and their use in the field of blood coagulation
CA2437587C (en) Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines and their use as anticoagulant and antithrombotic agents
WO2007042146A1 (de) Behandlung und prophylaxe von mikroangiopathien
CA2624323A1 (en) Combination therapy comprising substituted oxazolidinones for the prevention and treatment of cerebral circulatory disorders
EP1054886A1 (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
JP2009507055A (ja) イミノオキサゾリジン誘導体およびその使用
RU2836548C9 (ru) Замещенные оксазолидиноны, способы их получения, лекарственное средство на их основе и применение замещенных оксазолидинонов
AU2004202422B2 (en) Substituted oxazolidinones and their use in the field of blood coagulation
RU2836548C2 (ru) Замещенные оксазолидиноны, способы их получения, лекарственное средство на их основе и применение замещенных оксазолидинонов

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201211